Manuel Rivera Maza, MD
Interventional Cardiology · Muncie, INNPI 1144601816
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,044 of the $4,052 with a category attached, or 75.1%. 17 manufacturers reported payments, led by Boston Scientific at 32.9% of the total. Reporting peaked in 2023 at $2,502 and has fallen 97.1% since, to $72 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IN, where the typical reported total is $6,172.
Across 55 payments — averaging $73.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Abbott$678
- Philips North America LLC$467
- Siemens Medical Solutions USA, Inc.$269
- Abiomed$260
- Medtronic$251
- plus $792 from 11 others
Across 13 payments — averaging $1190.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$15K
What the payments were for
- Grants$2947%
- Travel & lodging$71418%
- Food & beverage$3,04475%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $1,334 |
| Abbott | 7 | $678 |
| Philips North America LLC | 5 | $467 |
| Siemens Medical Solutions USA, Inc. | 3 | $269 |
| Abiomed | 3 | $260 |
| Medtronic | 11 | $251 |
| Biotronik Inc. | 2 | $213 |
| Shockwave Medical, Inc | 2 | $195 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Inari Medical, Inc. | 1 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $37 |
| Irhythm Technologies, Inc. | 1 | $36 |
| Edwards Lifesciences | 1 | $33 |
| Novartis | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Terumo Medical Corporation | 1 | $22 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$460
- Diamondback Coronary$258
- Impella$254
- SOMATOM Force$197
- System SOMATOM Drive$197
- ROTAPRO$175
- AMPLATZER$173
- MitraClip$162
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$150
- MitraClip System$148
- (6571) Eagle Eye$138
- Orsiro Mission$125
- (6585) Omniwire$113
- (6494) Flowire$113
- SYNERGY$109
How this compares
$4,052 in reported general payments places this provider in the 35th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $88,614 |
| EntrestoSacubitril/Valsartan | 38 | $49,554 |
| JardianceEmpagliflozin | 35 | $44,708 |
| BrilintaTicagrelor | 24 | $23,661 |
| Ranolazine ErRanolazine | 25 | $3,616 |
| Atorvastatin Calcium | 120 | $989 |
| Metoprolol Succinate | 86 | $966 |
| Candesartan Cilexetil | 20 | $951 |
| Losartan Potassium | 99 | $822 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 48 | $752 |
| Torsemide | 33 | $650 |
| ClopidogrelClopidogrel Bisulfate | 51 | $562 |
| Carvedilol | 82 | $516 |
| Furosemide | 123 | $492 |
| Amlodipine Besylate | 82 | $485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $88,61465 claims |
| NovartisEntresto | $24 | $49,55438 claims |
| Boehringer IngelheimJardiance | $24 | $44,70835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Muncie
- Ali IqtidarMuncie$23K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.